Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06559332
Recruiting Not applicable

Coronary Artery Disease Assessment Strategies in TAVI Patients

NCT06559332 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Not applicable
Started
2025-03-11
Last updated
2026-05-08

Condition(s) studied

Transcatheter Aortic Valve ReplacementCoronary Artery DiseaseHeart Disease Risk Factors

Investigational drug(s) / intervention(s)

Risk-based CAD managementInvasive coronary angiography

Risk-based CAD management: Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.

Invasive coronary angiography: Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.

Study summary

Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.

As the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit/risk balance of routine invasive coronary angiography prior to transcatheter aortic valve implantation (TAVI) is unclear.

The CAT Trial aims to compare a non-invasive risk management strategy to routine invasive coronary angiography for the assessment of coronary artery disease in patients with severe, symptomatic aortic stenosis selected to undergo TAVI with respect to adverse clinical outcomes at 3 years (primary objective) and patient reported outcome measures (secondary objective).

Eligibility

Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
No
Inclusion: • Severe aortic stenosis defined by aortic valve area (AVA) ≤1cm2 AND mean gradient ≥40 mmHg or peak velocity ≥4.0 m/s OR if mean gradient \<40 mmHg and peak velocity (Vmax) \<4 m/s and stroke volume indexed to body surface area (SVi) ≤ 35 mL/m2 and LVEF ≥50% then if CT-derived aortic valve calcium score \>2000 Agatston units in men, \>1200 in women OR if mean gradient \<40 mmHg and Vmax \<4 m/s and SVi ≤ 35 mL/m2 and LVEF \<50% then if CT-derived aortic valve calcification \>2000 Agatston units in men, \>1200 in women OR if low-dose dobutamine stress echocardiography with flow reserve (\>20% increase in stroke volume) and AVA ≤1cm2 * Coronary calcium score ≥ 400 Agatston units (derived from routine pre-TAVI CT) or known coronary artery disease * Selected for treatment with transfemoral TAVI. * Written informed consent. Exclusion Criteria: * Concomitant valvular heart disease or ascending aortic aneurysm with indication for surgery or intervention * Unprotected left main coronary stenosis \>50% or left main not evaluable based on coronary computed tomography angiography derived from routine pre-TAVI CT * Left ventricular ejection fraction (LVEF) \< 30% * New regional wall motion abnormalities on echocardiography * Myocardial infarction in previous 12 months * Coronary angiography in previous 12 months * Prior left main stenting

Primary outcome measure(s)

  • Composite of all-cause death, myocardial infarction, any stroke, and heart failure hospitalization — 3 years
    Primary endpoint. Valve Academic Research Consortium (VARC)-3 definitions)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Bern, Department of Cardiology Bern Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Switzerland

Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) Starting soon
Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT Recruiting
Neck Rescue Access Comparison Enrolling by invitation
Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine Recruiting
Surrogating Physician-recorded SCORE2 Risk Calculator Inputs by Using Auxiliary Data Recruiting

Other trials for the same condition

The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial Recruiting
Randomized Comparison of Skeletonized Versus Pedicled Left Internal Thoracic Artery Recruiting
SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters Recruiting
Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure Recruiting
The SELUTION DeNovo Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06559332 on ClinicalTrials.gov ↗ ← All trials in Switzerland